Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 3
1(20.0%)
5Total
Phase 1(4)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03926624Phase 3Terminated

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Role: lead

NCT06382168Phase 1Recruiting

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

Role: lead

NCT03943004Phase 1Recruiting

Trial of DFP-14927 in Advanced Solid Tumors

Role: lead

NCT01702155Phase 1Completed

Phase I/II Study of DFP-10917 in Patients With Acute Leukemia

Role: lead

NCT02171221Phase 1Completed

Phase I Study of Oral DFP-11207 in Solid Tumors

Role: lead

All 5 trials loaded